Amir H. Ameri

Amir H. Ameri

Auto-generated profile, based on publicly available information

Amir H. Ameri

Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
LLLechen Li
Lechen Li
AAAmir H. Ameri
Amir H. Ameri
SWSimeng Wang
Simeng Wang
KJKeith H. Jansson
Keith H. Jansson
OCOrla M. Casey
Orla M. Casey
KKKathleen Kelly
Kathleen Kelly

29 January 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AAAmir H. Ameri
Amir H. Ameri
STSara Moradi Tuchayi
Sara Moradi Tuchayi
AZAnniek Zaalberg
Anniek Zaalberg
JPJong Ho Park
Jong Ho Park
KNKenneth H. Ngo
Kenneth H. Ngo
SDShadmehr Demehri
Shadmehr Demehri
Chronic inflammation’s tumor-promoting potential is well-recognized; however, the mechanism underlying the development of this immune environment is unknown. Studying the transition from acute, tumor-suppressive to chronic, tumor-promoting allergic contact dermatitis (ACD) revealed how tumor-promoting chronic inflammation develops. Epidermis-derived interleukin (IL)-33 up-regulation and its induction of regulatory T cell (Treg) accumulation in the skin preceded the transition from acute to chronic ACD and triggered the tumor-promoting immune environment in chronic ACD. Mice lacking IL-33 were protected from chronic ACD and its skin cancer sequela compared with wild-type controls (P = 0.0002). IL-33’s direct signaling onto Tregs was required for the development of the tumor-promoting immune environment in the skin. IL-33–Treg signaling was also required for chronic colitis and its associated colorectal cancer development in a colitis model (P < 0.0001). Significantly increased IL-33 and Tregs marked the perilesional skin and colon in patients with cancer-prone chronic inflammatory diseases. Our findings elucidate the role of the IL-33/Treg axis in creating a tumor-promoting immune environment in chronic inflammatory diseases and suggest therapeutic targets for cancer prevention and treatment in high-risk patients. Significance Chronic inflammatory diseases are well-recognized causes of cancer and account for up to 20% of all cancer deaths worldwide. However, the mechanism that initiates the development of a tumor-promoting immune environment in chronic inflammation is not known. Using mouse models of chronic skin and colon inflammation and human samples, we show IL-33 triggers the transition from tumor-suppressive immunity to chronic, tumor-promoting inflammation through a regulatory T cell-dependent mechanism. Our findings demonstrate a generalized dependency of tumor-promoting immune environments on the IL-33/Treg axis both in the skin and colon. Based on these findings, IL-33/Treg axis blockade may be an attractive therapeutic strategy for the treatment and prevention of cancers associated with chronic inflammatory diseases and potentiating the antitumor immunity induced by cancer immunotherapeutics.

1 December 2015 in Cell Reports
Verified
Journal Article
Open access
SASupreet Agarwal
Supreet Agarwal
PHPaul G. Hynes
Paul G. Hynes
HTHeather S. Tillman
Heather S. Tillman
RLRoss Lake
Ross Lake
Wassim Abou-KheirWassim Abou-Kheir
Wassim Abou-Kheir
KKKathleen Kelly
Kathleen Kelly
Primary prostate cancer almost always has a luminal phenotype. However, little is known about the stem/progenitor properties of transformed cells within tumors. Using the aggressive Pten/Tp53-null mouse model of prostate cancer, we show that two classes of luminal progenitors exist within a tumor. Not only did tumors contain previously described multipotent progenitors, but also a major population of committed luminal progenitors. Luminal cells, sorted directly from tumors or grown as organoids, initiated tumors of adenocarcinoma or multilineage histological phenotypes, which is consistent with luminal and multipotent differentiation potentials, respectively. Moreover, using organoids we show that the ability of luminal-committed progenitors to self-renew is a tumor-specific property, absent in benign luminal cells. Finally, a significant fraction of luminal progenitors survived in vivo castration. In all, these data reveal two luminal tumor populations with different stem/progenitor cell capacities, providing insight into prostate cancer cells that initiate tumors and can influence treatment response.

1 January 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AZAnniek Zaalberg
Anniek Zaalberg
STSara Moradi Tuchayi
Sara Moradi Tuchayi
AAAmir H. Ameri
Amir H. Ameri
KNKenneth H. Ngo
Kenneth H. Ngo
TCTrevor J. Cunningham
Trevor J. Cunningham
SDShadmehr Demehri
Shadmehr Demehri

1 June 2015 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
YLYen-Nien Liu
Yen-Nien Liu
JYJuanJuan Yin
JuanJuan Yin
BBBen Barrett
Ben Barrett
HSHeather Sheppard-Tillman
Heather Sheppard-Tillman
DLDongmei Li
Dongmei Li
KKKathleen Kelly
Kathleen Kelly
Bone metastasis is the hallmark of progressive and castration resistant prostate cancers. miR-1 levels are decreased in clinical samples of primary prostate cancer and further reduced in metastases. SRC has been implicated as a critical factor in bone metastasis, and here we show that SRC is a direct target of miR-1. In prostate cancer patient samples, miR-1 levels are inversely correlated with SRC expression and a SRC dependent gene signature. Ectopic miR-1 expression inhibited ERK signaling and bone metastasis in a xenograft model. In contrast, SRC overexpression was sufficient to reconstitute bone metastasis and ERK signaling in cells expressing high levels of miR-1. AR activity, defined by an AR output signature, is low in a portion of castration resistant prostate cancer. We show that AR binds to the miR-1-2 regulatory region, and regulates miR-1 transcription. Patients with low miR-1 levels displayed correlated low canonical AR gene signatures. Our data support the existence of an AR, miR-1, SRC regulatory network. We propose that loss of miR-1 is one mechanistic link between low canonical AR output and SRC promoted metastatic phenotypes.

5 August 2013 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
RKReju Korah
Reju Korah
JHJames Healy
James Healy
JKJohn W Kunstman
John W Kunstman
AFAnnabelle Fonseca
Annabelle Fonseca
AAAmir H Ameri
Amir H Ameri
TCTobias Carling
Tobias Carling
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with high mutational heterogeneity and a generally poor clinical outcome. Despite implicated roles of deregulated TP53, IGF-2 and Wnt signaling pathways, a clear genetic association or unique mutational link to the disease is still missing. Recent studies suggest a crucial role for epigenetic modifications in the genesis and/or progression of ACC. This study specifically evaluates the potential role of epigenetic silencing of RASSF1A, the most commonly silenced tumor suppressor gene, in adrenocortical malignancy.